Table 2.
Characteristics of patients with BCORMUT or BCORWT received decitabine therapy
| Characteristics | BCORWT (n = 181) | BCORMUT (n = 14) | p value |
|---|---|---|---|
| Age, median (range), year | 62 (17–85) | 62 (23–80) | 0.558 |
| Gender, male:female, n (%) | 120:61 (66:34) | 7:7 (50:50) | 0.250 |
| WHO/FAB classification, n (%) | 0.891 | ||
| RCMD | 47 (26.0) | 3 (21.4) | |
| RAEB-1 | 57 (31.5) | 3 (21.4) | |
| RAEB-2 | 39 (21.5) | 5 (35.7) | |
| RAEB-t | 12 (6.6) | 1 (7.1) | |
| CMML-1 | 17 (9.4) | 1 (7.1) | |
| CMML-2 | 9 (5.0) | 1 (7.1) | |
| IPSS risk, n (%) | 0.858 | ||
| Intermediate-1 | 84 (46.4) | 7 (50.0) | |
| Intermediate-2 | 77 (42.5) | 5 (35.7) | |
| High | 20 (11.1) | 2 (14.3) | |
| Cytogenetic risk group, n (%) | |||
| Good | 108 (59.7) | 12 (85.7) | 0.072 |
| Intermediate | 31 (17.1) | 2 (14.3) | |
| Poor | 42 (23.2) | 0 | |
| Decitabine cycles, median (range), n | 4 (1–11) | 4 (2–7) | 0.411 |